A Big Decision Is Fast-approaching For This Rare-disease Drugmaker

BioMarin (NASDAQ: BMRN), a massively successful rare-disease drugmaker that's already won six FDA approvals, is expected to find out this week if the FDA will gives it a seventh victory. The regulatory decision on pegvaliase, a new treatment for phenylketonuria, or PKU, has big implications for the company and its investors, so let's take a closer look.PKU is a rare genetic disease caused by an inability to break down phenylalanine, an amino acid.

Topics:  biomarin nasdaq   bmrn    source   images   fda   pku   big   decision   rare-disease drugmaker   foods   phenylalanine   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News